Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
Status: Enrolling
Updated:  6/30/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
Status: Enrolling
Updated: 6/30/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Allegheny General Hospital
mi
from
Pittsburgh, PA
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT:A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
Status: Enrolling
Updated:  8/1/2016
Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc
mi
from
Gilbert, AZ
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT:A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
Status: Enrolling
Updated: 8/1/2016
Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Cognitive Remediation for HIV-associated Neurocognitive Dysfunction
Plasticity-based Adaptive Cognitive Remediation (PACR) for HIV-associated Neurocognitive Dysfunction
Status: Enrolling
Updated:  11/22/2016
Posit Science Corporation
mi
from
San Francisco, CA
Cognitive Remediation for HIV-associated Neurocognitive Dysfunction
Plasticity-based Adaptive Cognitive Remediation (PACR) for HIV-associated Neurocognitive Dysfunction
Status: Enrolling
Updated: 11/22/2016
Posit Science Corporation
mi
from
San Francisco, CA
Click here to add this to my saved trials
Age-related Longitudinal Changes in Aviator Performance
Age-related Longitudinal Changes in Aviator Performance
Status: Enrolling
Updated:  12/5/2016
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Age-related Longitudinal Changes in Aviator Performance
Age-related Longitudinal Changes in Aviator Performance
Status: Enrolling
Updated: 12/5/2016
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Phenytoin for Memory Impairment Secondary to Megestrol
Phenytoin for Memory Impairment Secondary to Megestrol
Status: Enrolling
Updated:  12/28/2016
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Phenytoin for Memory Impairment Secondary to Megestrol
Phenytoin for Memory Impairment Secondary to Megestrol
Status: Enrolling
Updated: 12/28/2016
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated:  12/29/2016
Clinical Research Facility
mi
from
Baltimore, MD
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated: 12/29/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated:  12/29/2016
Clinical Research Facility
mi
from
Glendale, CA
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated: 12/29/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Status: Enrolling
Updated:  1/5/2017
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Status: Enrolling
Updated: 1/5/2017
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
CRI Lifetree
mi
from
Marlton, NJ
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
mi
from
Kobe,
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
mi
from
Kobe,
Click here to add this to my saved trials
Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older
Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older: Feasibility of Routine Screening and Utility for Predicting Morbidity
Status: Enrolling
Updated:  1/5/2017
Weiner Center for Preoperative Evaluation
mi
from
Boston, MA
Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older
Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older: Feasibility of Routine Screening and Utility for Predicting Morbidity
Status: Enrolling
Updated: 1/5/2017
Weiner Center for Preoperative Evaluation
mi
from
Boston, MA
Click here to add this to my saved trials
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
Status: Enrolling
Updated:  1/12/2017
New York State Psychiatric Institute
mi
from
New York, NY
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
Status: Enrolling
Updated: 1/12/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Memory and Mental Health in Aging
Memory and Mental Health in Aging: Psychopharmacological Augmentation of Memory Training in Older Adults
Status: Enrolling
Updated:  2/9/2017
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Memory and Mental Health in Aging
Memory and Mental Health in Aging: Psychopharmacological Augmentation of Memory Training in Older Adults
Status: Enrolling
Updated: 2/9/2017
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
UCSD
mi
from
San Diego, CA
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
UCSD
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
University of Miami School of Medicine
mi
from
Miami, FL
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Energy Metabolism and Cognitive Aging
Energy Metabolism and Cognitive Aging
Status: Enrolling
Updated:  3/23/2017
University of Cincinnati
mi
from
Cincinnati, OH
Energy Metabolism and Cognitive Aging
Energy Metabolism and Cognitive Aging
Status: Enrolling
Updated: 3/23/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oral Health Intervention Pilot Study for Individuals With Memory Problems
Developing a Caregiver-assisted Oral Health Intervention for Individuals With Memory Problems
Status: Enrolling
Updated:  3/29/2017
Duke University
mi
from
Durham, NC
Oral Health Intervention Pilot Study for Individuals With Memory Problems
Developing a Caregiver-assisted Oral Health Intervention for Individuals With Memory Problems
Status: Enrolling
Updated: 3/29/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Phenytoin and Driving Safety
Phenytoin and Driving Safety
Status: Enrolling
Updated:  5/8/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Phenytoin and Driving Safety
Phenytoin and Driving Safety
Status: Enrolling
Updated: 5/8/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
Status: Enrolling
Updated:  5/19/2017
Riley Hospital, Riley Child and Adolescent Psychiatry Clinic
mi
from
Indianapolis, IN
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
Status: Enrolling
Updated: 5/19/2017
Riley Hospital, Riley Child and Adolescent Psychiatry Clinic
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Genetic Contributions to Autism Spectrum Disorders
Genetic Contributions to Autism Spectrum Disorders
Status: Enrolling
Updated:  5/30/2017
Boston Children's Hospital
mi
from
Boston, MA
Genetic Contributions to Autism Spectrum Disorders
Genetic Contributions to Autism Spectrum Disorders
Status: Enrolling
Updated: 5/30/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Rutgers University-Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Rutgers University-Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Richmond Behavior Associates
mi
from
Staten Island, NY
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Richmond Behavior Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
Working on Rapid Language Development in Toddlers
An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders
Status: Enrolling
Updated:  6/27/2017
Vanderbilt University
mi
from
Nashville, TN
Working on Rapid Language Development in Toddlers
An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders
Status: Enrolling
Updated: 6/27/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
Galiz Research
mi
from
Hialeah, FL
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
Galiz Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
Mt. Sinai Wien Center for Alzheimer's Disease
mi
from
Miami Beach, FL
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
Mt. Sinai Wien Center for Alzheimer's Disease
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
Compass Research LLC
mi
from
Orlando, FL
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
SIU School of Medicine
mi
from
Springfield, IL
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
SIU School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated:  7/25/2017
McLean Hospital
mi
from
Belmont, MA
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Status: Enrolling
Updated: 7/25/2017
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials